Global Health Limited (NSE: MEDANTA), one of the largest private multi-specialty tertiary care providers in India, announced its audited consolidated financial results for the year ending 31st March, 2026. The company reported consolidated total income of INR 45,089 million, marking a strong growth of 19.6% year-on-year (y-o-y). The EBITDA (excluding Noida) grew by 18.6% y-o-y to INR 11,343 million with margins of 25.7%.

Key Financial Highlights

The consolidated total income for the year ended 31st March, 2026, was INR 45,089 million, up by 19.6% y-o-y. The profit after tax (PAT) was INR 5,541 million, showing a growth of 15.1% y-o-y. The board of directors recommended a final dividend of 25% on the face value of INR 2 per share, amounting to INR 0.50 per share. The EBITDA including Noida was INR 10,560 million, with margins at 24.2%.

Operational Growth

The company added a total of 623 beds during the year, reflecting a 20.5% bed growth. The newly operationalized Medanta Noida, with 382 beds and 14 operating theatres, reported revenue of INR 906 million and an EBITDA loss of INR 783 million in FY2026. The hospital is steadily gaining momentum, with quarterly start-up losses showing a declining trend. The total bed count increased by 20.5% y-o-y, with 131 beds added at Patna and 110 beds at the newly constructed hospital in Ranchi.

Inpatient count increased by 16.0% y-o-y and outpatient count by 18.7% y-o-y. The average occupied bed days increased by 11.3% y-o-y, representing an occupancy of ~62% on the increased bed capacity. The average revenue per occupied bed (ARPOB) grew by 6.1% y-o-y to INR 66,550, driven by improvement in average length of stay (ALOS) and change in case mix.

The mature hospitals’ revenue was INR 28,482 million, growing by 9.0% y-o-y. EBITDA for mature hospitals was INR 6,946 million, up by 7.2% y-o-y. Developing hospitals, excluding Noida, reported revenue of INR 14,130 million, growing by 29.2% y-o-y. EBITDA increased by 35.2% y-o-y to INR 4,447 million, with margins improving to 31.5% compared to 30.1% in FY25.

International patients’ revenue increased by 33.2% y-o-y to INR 2,780 million. OPD pharmacy revenue, including hospital and retail, registered strong double-digit growth, increasing by 30.4% y-o-y to INR 1,826 million in FY26.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Global Health Limited

Global Health Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Global moves sideways over three months, with neither buyers nor sellers taking control. The business compounds revenue at 18.8% and profits at 34.9% CAGR. That is strong double-digit growth on both counts. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock holds at 51% of its 52-week range with RSI at 64. In other words, neither side has a clear edge right now. The stock rises 6.4% in three months on 18.8% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Global Health Limited.